UTv Videos

Veda N. Giri, MD, outlines practical ways to improve prostate cancer genetic testing uptake and impact.

Amy N. Luckenbaugh, MD, FACS, shares what her patients have taught her about resilience as well as some of the advances in urologic oncology that are giving her hope.

Kate Kraft, MD, MHPE, FACS, FAAP, discusses her SWIU 2026 session on helping early-career urologists find their “leadership flow.”

Break Wave lithotripsy uses low-pressure, repeated pulses that generate standing stress waves within the stone.

Kristen R. Scarpato, MD, MPH, discusses what level of evidence is necessary to shift the standard of care in BCG-naive NMIBC.

Amanda C. North, MD, reflects on key takeaways from a panel discussion on imposter syndrome.

Farah Rahman, MD, MPH, highlights a pilot study on the use of wearable biofeedback technology to better understand and address burnout among urology residents.

Regarding acceptable risk thresholds, Alam describes himself as relatively risk-averse, favoring a 5% to 10% miss rate for Grade Group 2 or higher disease when considering biopsy avoidance.

John P. Sfakianos, MD, shares the clinical rationale for the phase 2 ENHANCE trial, evaluating the addition of NKG2A inhibition to PD-1/PD-L1 inhibition in NMIBC.

Veda N. Giri, MD, shares key findings from the PROGRESS Registry, which evaluated patient-reported outcomes with prostate cancer genetic testing.

Pedro F.S. Freitas, MD, recaps his talk at the 2026 Desai Sethi Urology Institute Urology on the Beach meeting.

Sudha Jayaraman, MD, MSc, FACS, recaps a session from the 2026 Urology on the Beach meeting focused on AI in health care.

Although BCG has been the standard of care for decades and remains the most effective available treatment, outcomes remain suboptimal for many patients.

Lina Posada Calderon, MD, discusses the background and key takeaways from her team’s study examining germline BAP1-associated renal cell carcinoma.

Alam frames PHI and MRI as noninvasive tools that help refine risk before proceeding to biopsy.

Despite improvements, Kalyani Narra, MD, highlights persistent gaps in referral among eligible patients.

John P. Sfakianos, MD, outlines the scientific rationale for combining systemic immunotherapy with BCG in the BCG-naïve NMIBC setting.

Wesley Hauwei Chou, MD, outlined 2 projects evaluating potential biomarkers for treatment response in renal cell carcinoma.

When symptoms appear tied to the menstrual cycle, pharmacologic options can be used as short-term support.

Iman Sadri, MD, CM, discusses a somatic-autonomic nerve grafting technique for patients with persistent erectile dysfunction after radical prostatectomy.

The session emphasized how rapidly evolving AI technologies are addressing long-standing inefficiencies in urologic care.

Walter R. Hsiang, MD, MBA, highlights a study looking at access to care, insurance acceptance, wait times, and costs for stone disease management.

Aleece Fosnight, MSPAS, PA-C, highlights pattern recognition as a cornerstone of diagnosis, encouraging clinicians to closely examine how urinary symptoms fluctuate across the menstrual cycle.

A key finding was that among the qualities applicants highlighted, only “learning and growth” correlated with interview selection.

Maxwell L. Sandberg, MD, highlights a study on survival outcomes between patients who underwent CN-TT via an open, laparoscopic, or robotic approach.

Notable findings highlighted stark differences between this safety-net population and national averages.

Fed Ghali, MD, discusses the phase 2 CONSOLIdaTE-01 trial, assessing the role for consolidative local therapy following disease control on EV/P.

Jennifer Miles-Thomas, MD, URPS, MBA, emphasizes that teleurology and team-based care models offer significant promise